Epidemiology and Social: EDITORIAL COMMENT
Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons
Soriano, Vincent; Sheldon, Julie; Ramos, Belén; Núñez, Marina
From the Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
Received 29 August, 2004
Revised 13 September, 2005
Accepted 20 October, 2005
Correspondence to Dr V. Soriano, Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain. E-mail: email@example.com
Hepatitis B virus (HBV) is a small enveloped DNA virus that replicates by reverse transcription of the pregenomic RNA using a virus-encoded polymerase. This enzyme lacks proofreading activity, which results in wide virus sequence heterogeneity. Phylogenetic analyses have led to the recognition of eight HBV genotypes (A to H) on the basis of > 8% divergence in the complete genome. As shown in Table 1, evidence for differences in geographic distribution, viral markers, liver pathogenicity and treatment susceptibility for HBV genotypes have emerged in recent years [1–3].
Multiple factors influence liver disease progression in patients with chronic HBV infection, including age at infection, serum HBV DNA titres, alcohol consumption and concomitant infection with hepatitis C or delta viruses. Concurrent HIV infection is associated with accelerated liver fibrosis progression . Given the growing evidence for a distinct behaviour of HBV genotypes, studies on the molecular epidemiology of HBV in HIV-positive individuals are very welcomed [5,6]. In this issue of AIDS, Lacombe et al.  report the results of a cross-sectional study conducted in 2002 and 2003 in seven French hospitals, in which 104 HBV/HIV-coinfected patients were identified and underwent a liver biopsy. HBV genotype A was the most prevalent (72%), followed by genotype G (12%), D (10%) and E (6%). Interestingly, advanced liver fibrosis (METAVIR scores F2–F4) was recognized in 69% of patients and the main predictor of advanced liver fibrosis was infection by HBV genotype G.
Recent guidelines [8,9] have recommended that serum HBV soluble antigen (HBsAg) should be screened in all HIV-infected individuals. In those who are positive, full serological assessment of markers of HBV infection should be performed, including testing of HBV e antigen (HBeAg) and anti-HBeAg antibody, and plasma HBV DNA measurement. HBV treatment must be considered for patients with active disease and viral replication [10,11]. In HBV-monoinfected subjects, the indication for therapy until recent years often relied on histological findings. With the advent of new oral drugs and the chance to measure serum HBV DNA levels, the need for a liver biopsy has diminished [10,11]. Moreover, new non-invasive tools for assessing liver fibrosis, such as elastography (FibroScan)  and/or serum fibrosis markers , have allowed liver biopsies to be avoided in many circumstances, further providing an opportunity for periodic longitudinal assessment of these patients.
While there is an association between serum HBV DNA titres and liver damage in patients with chronic HBV infection, the minimal threshold of plasma HBV DNA associated with progressive liver disease is unknown. Recent guidelines in HIV-negative persons with chronic HBV hepatitis have recommended that treatment should be considered for HBeAg-positive patients with serum HBV DNA > 105 copies/ml [10,11]. A lower threshold seems to be appropriated for HBeAg-negative patients and those with decompensated cirrhosis (thresholds of 104 and 103 copies/ml, respectively). At this time, the recommendations for treating HBV in the setting of HIV coinfection are that an individual decision should be made based additionally on considerations related to HIV status and, particularly, the need for antiretroviral therapy [8,9]. Clearly, coexistence of HIV infection with chronic HBV infection makes necessary an integrated approach for the appropriate management of both infections.
For patients with detectable HBV viraemia and who have already received lamivudine, HBV resistance should be suspected. Lacombe and colleagues  found lamivudine-resistant HBV-associated mutations in more than two-thirds of their HBV/HIV-coinfected population. Emtricitabine is not useful in this setting against HBV, and switching to or adding tenofovir may be advisable. If HIV replication is already suppressed, adding adefovir or entecavir are also reasonable options in this subset of patients.
The introduction of tenofovir into the HBV armamentarium for HIV-coinfected patients (Table 2) has provided new hopes [14–20]. The high genetic barrier for resistance to nucleotide reverse transcriptase inhibitors (adefovir and tenofovir) represents an advantage with respect to the L-nucleosides lamivudine and emtricitabine. Furthermore, these two families of drugs do not show cross-resistance, which makes possible salvage interventions and more attractive combination therapy . A new nucleoside analogue, entecavir, which shows high potency and robust resistance barrier, has recently been approved for the treatment of HBV. However, no doubt resistance will emerge as result of prolonged therapy with any of these compounds, as has recently been pointed out with tenofovir .
In summary, the availability of new HBV diagnostic tools, including genotyping, viral load measurement and resistance testing has come to maturity. Their use will allow more adequate approaches to chronic HBV hepatitis. These tests may permit estimation of the risk of progression of HBV-related liver disease and the tailoring of HBV therapy and monitoring on an individual basis. Consequently, efforts should be made to introduce them into the clinic as soon as possible. Clearly, a new era has begun and this is time to change our approach to HBV in the HIV setting.
Sponsorship: This work was supported in part by grants from Red de Investigación en SIDA (RIS G03/173), Fundación Investigación y Educación en SIDA (IES) and the VIRGIL European Network of Excellence on Antiviral Drug Resistance (LSHM-CT-2004-503359).
1. Stuyver L, de Gendt S, van Geyt C, Zoulim F, Fried M, Schinazi R, et al
. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81:67–74.
2. Fung S, Lok A. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004; 40:790–792.
3. Kramvis A, Kew M. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 2005; 12:456–464.
4. Colin J, Cazals-Hatem D, Loriot M, Martinot-Peignoux M, Pham B, Auperin A, et al
. Influence of HIV infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306–1310.
5. Perez-Olmeda M, Núñez M, García-Samaniego J, Soriano V. Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. AIDS Res Human Retroviruses 2003; 19:657–659.
6. Shibayama T, Masuda G, Ajisawa A, Hiruma K, Tsuda F, Nishizawa T, et al
. Characterization of seven genotypes (A to E, G and H) of hepatitis B virus recovered from Japanese patients infected with HIV type 1. J Med Virol 2005; 76:24–32.
7. Lacombe K, Massari V, Girard P, Serfaty L, Faure V, Gozlan J, et al
. Major role of hepatitis B genotypes in liver fibrosis in HIV-HBV coinfection. AIDS 20
8. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al
. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19:221–240.
9. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al
. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615–624.
10. Keeffe E, Dieterich D, Han S-H, Jacobson I, Martin P, Schiff E, et al
. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2:87–106.
11. Lok A, McMahon B. Chronic hepatitis B: update of recommendations. AASLD Practice Guidelines. Hepatology 2004; 39:857–861.
12. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al
. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343–350.
13. Myers R, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, et al
. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003; 17:721–725.
14. Núñez M, Pérez-Olmeda M, Díaz B, Ríos P, González-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16:2352–2354.
15. van Bömmel F, Wünsche T, Schürmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36:507–508.
16. Ristig M, Crippin J, Aberg J, Powderly W, Lisker-Melman M, Kessels L, et al
. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in HIV/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed. J Infect Dis 2002; 186:1844–1847.
17. Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, et al
. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17:F7–F10.
18. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348:177–178.
19. Dore G, Cooper D, Pozniak A, De Jesus E, Zhong L, Miller M, et al
. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV and hepatitis B virus. J Infect Dis 2004; 189:1185–1192.
20. Lacombe K, Gozlan J, Boelle P, Sefaty L, Zoulim F, Valleron AJ, et al
. Long-term hepatitis B virus dynamics in HIV-HBV co-infected patients treated with tenofovir disoproxil fumarate. AIDS 19
21. Puoti M, Cozzi-Lepri A, Ancarani F, Bruno R, Ambu S, Tundo P, et al
. The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug? Antivir Ther 2004; 9:811–817.
22. Sheldon J, Camino N, Rodes B, Batholomeusz A, Kuiper M, Tacke F, et al
. Selection of hepatitis B virus resistance mutations in HIV co-infected patients treated with tenofovir. Antivir Ther 2005; 10:456–465.
hepatitis B; HIV; tenofovir; lamivudine; adefovir; interferon; entecavir
© 2006 Lippincott Williams & Wilkins, Inc.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Highlight selected keywords in the article text.
Data is temporarily unavailable. Please try again soon.
Readers Of this Article Also Read